Therapeutic effect and safety of acipimox combined with small-dose atorvastatin on combined hyperlipidemia after renal transplantation
10.3969/j.issn.1674-7445.2015.06.009
- VernacularTitle:阿西莫司联合小剂量阿托伐他汀治疗肾移植术后混合型高脂血症的疗效与安全性
- Author:
Xing WEI
1
;
Ming CAI
;
Xiang LI
;
Hailong JIN
;
Dawei ZHANG
Author Information
1. 解放军第 309 医院全军器官移植研究所泌尿一科
- Keywords:
Renal transplantation;
Combined hyperlipidemia;
Atorvastatin;
Acipimox
- From:
Organ Transplantation
2015;(6):392-396,414
- CountryChina
- Language:Chinese
-
Abstract:
Objective To assess the therapeutic effect and safety of acipimox combined with small-dose atorvastatin on combined hyperlipidemia after renal transplantation. Methods Fifty-six patients complicated with combined hyperlipidemia after renal transplantation were randomized into the combined small-dose group [n =28,acipimox (250 mg,twice a day) +atorvastatin (1 0 mg,once a day)]and normal dose group [n =28,atorvastatin (20-40 mg,once a day)].Total cholesterol (TC),triglyceride (TG),high density lipoprotein cholesterin (HDL-C ), low density lipoprotein cholesterin (LDL-C ), aspartate aminotransaminase (AST),alanine aminotransferase (ALT),serum creatinine (Scr),blood urea nitrogen (BUN),uric acid (UA)and creatine kinase (CK)were observed before treatment and 1 ,2 and 3 months after treatment.Adverse drug reaction was recorded.Results Compared with those before treatment,TC,TG and LDL-C of the normal dose group and the combined small-dose group decreased after treatment,but HDL-C increased,and the difference had statistical significance (all in P <0.01 ).Compared with the normal dose group,TG and LDL-C of the combined small-dose group were lower and HDL-C was higher,and the difference had statistical significance (all in P <0.01 ).At each time point before and after treatment,ALT,AST,Scr, BUN,UA and CK of the normal dose group and the combined small-dose group showed no statistically significant difference (all in P >0.05).There was significant difference in the incidence of adverse reactions in the digestive system,nervous system,musculoskeletal system and skin/vascular of the normal dose group and the combined small-dose group (all in P <0.05 ).Conclusions Acipimox combined with small-dose atorvastatin can treat combined hyperlipidemia after renal transplantation safely and effectively.
